- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST SITE INITIATED IN A REGISTRATIONAL STUDY OF GFH375 FOR METASTATIC PANCREATIC CANCER, AS FIRST-IN-WORLD ... | 1 | HKEx | ||
| 24.11. | GENFLEET-B (02595): PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| 22.10. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A PHASE IB/II STUDY OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, COMBINED WITH CETUXIMAB ... | 2 | HKEx | ||
| 21.10. | Verastem stock falls after GenFleet's PDAC study shows lower efficacy data | 1 | Investing.com | ||
| 21.10. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.10. | GENFLEET-B (02595): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.10. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 20.10. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT EFFICACY DATA OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FOR PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS ... | 1 | HKEx | ||
| 19.10. | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | 538 | Business Wire | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| 16.10. | GENFLEET-B (02595): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | - | HKEx | ||
| 15.10. | GENFLEET-B (02595): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 15.10. | GENFLEET-B (02595): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 30.09. | GENFLEET-B (02595): 2025 INTERIM REPORT | 1 | HKEx | ||
| 29.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT ... | - | HKEx | ||
| 19.09. | GENFLEET-B (02595): DATE OF BOARD RESOLUTIONS AND DATE OF PUBLICATION OF INTERIM REPORT | 1 | HKEx | ||
| 19.09. | BRIEF: GenFleet shares double in heavily oversubscribed IPO | 1 | Bamboo Works | ||
| 18.09. | GENFLEET-B (02595): ANNOUNCEMENT OF ALLOTMENT RESULTS | 3 | HKEx | ||
| 18.09. | GENFLEET-B (02595): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.09. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.09. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| COGENT BIOSCIENCES | 41,620 | +3,95 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| LENZ THERAPEUTICS | 18,095 | -26,17 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| BIONTECH | 80,90 | -1,04 % | Märkte am Morgen: Nvidia, Netflix, Paramount Skydance, Bayer, HelloFresh, BioNTech, ASML | Die Sitzung der US-Notenbank am Mittwoch ist das beherrschende Thema in dieser Woche. Am deutschen Aktienmarkt zeigte sich der DAX im Vorfeld zurückhaltend, schloss aber immerhin leicht in der Gewinnzone.... ► Artikel lesen | |
| VOR BIOPHARMA | 12,810 | +5,35 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,420 | -3,49 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 32,900 | +4,28 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| AVIDITY BIOSCIENCES | 71,70 | +0,14 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| ARCUS BIOSCIENCES | 22,270 | -11,45 % | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,320 | +7,17 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 89,06 | +1,42 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,510 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 68,30 | +1,28 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOVANT | 26,350 | +6,21 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.